Sansure Biotech(SH:688289) Xiangcai Securities·2025-03-05 01:44Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Viewpoints - The company plans to acquire 54% of Hong'an Jiyuan's equity through self-funding, enhancing its blood cell detection capabilities and expanding its ecosystem [1] - Hong'an Jiyuan focuses on the production and sales of blood cell analyzers in the POCT field, with a strong growth trajectory and established supply chain [2] - The company has ample cash reserves exceeding 4.5 billion, indicating a proactive approach to external exploration and development [3] - Revenue projections for 2024-2026 are set at 1.445 billion, 1.959 billion, and 2.491 billion respectively, with net profits of 315 million, 459 million, and 626 million [4] Summary by Sections Acquisition Details - The company will invest a total of 75.6 million to acquire 54% of Hong'an Jiyuan, which had total assets of 14.702 million and a net profit of -12.8406 million for 2024 [1] Business Expansion - Hong'an Jiyuan, established in July 2022, is rapidly expanding in the blood cell analyzer market, targeting low penetration rates in community health centers and clinics [2] - The company has developed a systematic supply chain and sales team, achieving significant installations of blood cell analyzers across multiple provinces since its product launch in 2024 [2] Financial Position - As of Q3 2024, the company holds over 4.5 billion in cash and financial assets, indicating strong liquidity for future investments [3] - The company has been actively acquiring stakes in various technology platforms since 2021, including gene sequencing and chemiluminescence [3] Financial Forecast - Revenue and net profit forecasts for 2024-2026 are maintained at 1.445 billion, 1.959 billion, and 2.491 billion for revenue, and 315 million, 459 million, and 626 million for net profit respectively [4]